November 22, 2019
  • November 22, 2019
Breaking News
  • Home
  • Health
  • Healthcare Mover: Acasti Pharma Inc. (NASDAQ:ACST), Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb Company (NYSE:BMY)

Healthcare Mover: Acasti Pharma Inc. (NASDAQ:ACST), Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb Company (NYSE:BMY)

By on June 27, 2019 0

Acasti Pharma Inc. (NASDAQ:ACST) loss for fiscal 2019 expanded from $21.5 million in the prior year to $51.6 million due to higher R&D costs for the TRILOGY Phase 3 program and other financial expenses. The company ended the year with $34.4 million in cash $26.2 million more than than the prior year on the basis of net proceeds from public offerings in May and October.

Acasti Pharma Inc. (NASDAQ:ACST) shares advanced 14.29% to finally closed at $1.20 in last active session. 

ACST’s distance from 20 day simple moving average is 30.95% and distance from 50-Day simple moving average is 34.92%.

Analyst’s mean target price for ACST is $2.52 while analysts mean recommendation is 2.00. Stock value has moved between $0.43 – 1.79 in last one year. Stock has got OUTPERFORM rating from 1 of Thomson Reuters analysts, 0 given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for ACST is $2.52 while analysts mean recommendation is 2.00. 

Acasti Pharma Inc. (NASDAQ:ACST) yearly performance is 76.47%. The current share price indicates that stock is -33.33% away from its one year high and is moving 176.94% ahead of its 52-week low. 



On 26 June 2018, Pfizer Inc. (NYSE:PFE) shares shed -1.76% and ultimately finalized to $42.99 in last traded day. Stock has got OUTPERFORM rating from 6 of Thomson Reuters analysts, 5 given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for PFE is $45.57 while analysts mean recommendation is 2.40. 



At the movement Bristol-Myers Squibb Company (NYSE:BMY) is under coverage by number of analysts. Buy rating has been given by 3 analysts to the company stock whereas 0 given UNDERPERFORM rating to stock and 7 given HOLD rating. The consensus recommendation by Thomson Reuters analysts is outperform and their mean rating for the stock is 2.33 on scale of 1-5. Analysts mean target price for Bristol-Myers Squibb Company (NYSE:BMY) is $56.10 while their mean recommendation is 2.30 (1=Buy, 5=sell). 

If we look at stock performance in last active day trading, we see that stock has moved shed -1.86% to end the day at $44.92. The current share price indicate that stock is -29.47% away from its one year high and is moving 1.40% ahead of its 52-week low. 

Leave a comment